• 1
    Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-IgE antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632638.
  • 2
    Stanworth DR, Humphrey JH, Bennich H, Johansson SGO. Inhibition of Prausnitz-Kustner reaction by proteolytic-cleavage fragments of a human myeloma protein of immunoglobulin class E. Lancet 1968;2:1718.
  • 3
    Holt PG, Macaubras C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402(Suppl.):B12B17.
  • 4
    Casolaro V, Spadaro G, Marone G. Human basophil releasability: VI. Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma. Am Rev Respir Dis 1990;142:11081111.
  • 5
    Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R et al. Basophil allergen threshold sensitivity. A useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006;61:298302.
  • 6
    Holgate ST. Implications for clinical practice, in anti-IgE therapy. A new era in the control of severe persistent allergic asthma? European Respiratory Society Congress, Copenhagen, 19 September 2005.
  • 7
    Xolair (omalizumab), Summary of Product Characteristics:
  • 8
    Bennich HH, Ishizaka K, Johansson SGO, Rowe DS, Stanworth DR, Terry WD. Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968;38:151152.
  • 9
    Johansson SGO, O'B Hourihane J, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813824.
  • 10
    Host A, Andrae S, Charkin S, Diaz-Vazquez C, Dreborg S, Eigenmann PA et al. Allergy testing in children: why, who, when and how? Allergy 2003;58:111.
  • 11
    Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491498.
  • 12
    MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, Mckenzie-White J et al. Down-regulation of Fc(epsilon)RI expression in human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:14381445.
  • 13
    Simpson A, Soderstrom L, Ahlstedt S, Murray CS, Woodcock A, Custovic A. IgE antibody quantification and the probability of wheeze in preschool children. J Allergy Clin Immunol 2005;116:744749.
  • 14
    Nopp A, Johansson SGO, Lundberg M, Öman H. Simultaneous exposure of several allergens has an additive effect on multisensitized basophils Allergy: Doi: 10.1111/j.1398-9995.2006.01211.x